Margarida Maia, PhD,  science writer—

Patients being treated with Isturisa (osilodrostat) for Cushing’s disease see better long-term clinical outcomes when both late-night salivary cortisol and mean urinary free cortisol returned to normal levels, instead of just one or neither of those measures. Drawing on data from two Phase 3 clinical studies, LINC-3…

All patients who completed a Phase 2 clinical trial of clofutriben, an oral small molecule that Sparrow Pharmaceuticals is developing for endogenous Cushing’s syndrome, chose to continue on the experimental treatment as part of a planned open-label extension. Overall, the results of the trial, dubbed RESCUE, showed promise, Sparrow…

Yana Zavros, PhD, a physiologist working on Cushing’s disease, has been named the Georgia Research Alliance’s eminent scholar in molecular medicine. She will establish and direct a new research center at the University of Georgia’s School of Medicine, focusing on translating laboratory observations into clinical practice. The center will…

Cushing’s disease appears to be on the rise in Iceland, a study finds, underscoring the importance of an early diagnosis. “Advances in diagnostic and treatment options is probably the strongest cause of increased incidence in the later years, but other factors such as genetics can also play a role,”…

A 76-year-old man in Greece developed ectopic Cushing’s syndrome due to an advanced prostate cancer that started producing the adrenocorticotropic hormone (ACTH), leading to unusual symptoms such as muscle weakness, slowed thinking, and low potassium levels. Despite immediate treatment, his clinical condition worsened, and he eventually died. It’s a…

A 71-year-old woman developed cyclic Cushing’s syndrome, where periods of hypercortisolism alternate with periods of normal or low cortisol levels, as the result of a pheochromocytoma, a rare type of tumor that forms in the adrenal glands atop the kidneys. Cushing’s syndrome is due to high cortisol levels, or…

Sparrow Pharmaceuticals’ oral small molecule SPI-62, now being called clofutriben, can lower the levels of free cortisol in the urine of people with Cushing’s syndrome caused by a tumor outside the adrenal glands, including those with Cushing’s disease. Unlike other cortisol-lowering medications, which require careful dosing to prevent…

People with Cushing’s syndrome, including those with Cushing’s disease, appear to have more heart issues — like poorer heart function and larger ventricles, which are the heart’s lower chambers — compared with other patients with similar cardiovascular risk factors, a study using MRI imaging has found. The heart issues…

The presence of somatic mutations in the USP8 gene, found in up to half of people with Cushing’s disease, appears to have no impact on how well patients fare after undergoing surgery to remove a disease-causing pituitary tumor, a study has found. However, patients with USP8 mutations — all…

For people who undergo surgery to treat Cushing’s disease or other forms of endogenous Cushing’s syndrome, replacement treatment with glucocorticoids may not be necessary immediately before or after the procedure, a study suggests. Rather, findings favored “withholding perioperative glucocorticoids until the first postoperative day (or even longer),” the researchers…